Cargando…

Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer

Immune checkpoint blockade (ICB) has changed the standard of care for many patients with cancer, yet no ICB is approved for ovarian cancer. We hypothesized that maintenance therapy with an IL15 “superagonist” (N-803) and ICB in combination could induce potent immune activation in ovarian cancer. Usi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Felices, Martin, Wesley, Erin, Bendzick, Laura E., Kodal, Behiye, Hopps, Rachel, Grzywacz, Bartosz, Hinderlie, Peter, Miller, Jeffrey S., Geller, Melissa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155036/ https://www.ncbi.nlm.nih.gov/pubmed/36807510 http://dx.doi.org/10.1158/2326-6066.CIR-22-0600

Ejemplares similares

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
por: Kaminski, Michael F, et al.
Publicado: (2022)

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
por: Vallera, Daniel A., et al.
Publicado: (2021)

Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
por: Myers, Jacob A., et al.
Publicado: (2022)

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
por: Vallera, Daniel A., et al.
Publicado: (2020)

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer
por: Kennedy, Philippa R., et al.
Publicado: (2023)

Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy
por: Yao, Yongrong, et al.
Publicado: (2022)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
por: Yi, Ming, et al.
Publicado: (2019)

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
por: Lee, Ju Yeon, et al.
Publicado: (2016)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2018)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy
por: Wang, Dongdong, et al.
Publicado: (2023)

The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer
por: Yazici, Gozde, et al.
Publicado: (2018)

Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
por: Gubin, Matthew M., et al.
Publicado: (2014)

A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
por: Guram, Kripa, et al.
Publicado: (2019)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Duan, Xiaopin, et al.
Publicado: (2019)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
por: Lin, Xiaoning, et al.
Publicado: (2021)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
por: Yang, Jing, et al.
Publicado: (2022)

Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
por: Lee, Junghwa, et al.
Publicado: (2023)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
por: Roy, Dia, et al.
Publicado: (2023)

Integrin α(v)β(3)-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
por: Chen, Haojun, et al.
Publicado: (2019)

Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
por: Zhao, Jun, et al.
Publicado: (2019)

Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation
por: Yang, Jianbo, et al.
Publicado: (2021)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy
por: Ni, Kaiyuan, et al.
Publicado: (2018)

The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy
por: Zhao, Huan, et al.
Publicado: (2018)

NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy
por: Yoshihama, Sayuri, et al.
Publicado: (2021)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
por: Sun, Shangqin, et al.
Publicado: (2021)

Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy
por: Luby, Angèle, et al.
Publicado: (2021)

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy
por: Zhao, Peiqi, et al.
Publicado: (2022)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine‐Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles
por: Wang, Tingting, et al.
Publicado: (2023)

Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review
por: Uppendahl, Locke D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jk1q1mshv3vka5850smiklntkm